CTIS2023-505940-20-00招募中1 期
The Optimised use of Romosozumab Study
Region Midtjylland0 个研究点目标入组 270 人开始时间: 2023年5月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •postmenopausal women, Osteoporosis defined as BMD T-score < -2.5 at spine, total hip or femoral neck, Osteoporotic fracture at spine, hip, pelvis, forearm, or humerus within 3 years after the age of 50 years
排除标准
- •Osteoporosis treatment within the last 5 years, Metabolic bone disease, Known disorders affecting bone metabolism, Ongoing treatment with glucocorticoids, Estimated glomerular filtration rate (eGFR) < 35 ml/min, Contraindications or intolerance to romosozumab or zoledronate
研究者
相似试验
招募中
不适用
Evaluation of efficacy and safety of romosozumab administration group and ibandronate sodium hydrate administration group for osteoporosis patients after denosumab treatmentosteoporosisJPRN-UMIN000037394Shinshu University School of Medicine Dept. of Orthopaedic Surgery60
尚未招募
不适用
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumabosteoporosisJPRN-UMIN000037123Shinshu University School of Medicine Dept. of Orthopaedic Surgery60
招募中
4 期
The Optimised Use of Romozosumab StudyOsteoporosisNCT06059222University of Aarhus270
已完成
2 期
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral DensityLow Bone Mineral DensityPostmenopausal OsteoporosisNCT00896532Amgen419
已完成
1 期
A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal WomenOsteopeniaNCT01059435Amgen74